Oxfordshire Clinical Commissioning Group
Formulary
 
back
10 Musculoskeletal and joint diseases
10-01-03 Drugs which suppress the rheumatic disease process

Tofacitinib citrate Xeljanz®
Formulary

For treating

  • moderate to severe rheumatoid arthritis as per NICE TA480 (APCO November 2017).
  • active psoriatic arthritis after inadequate response to DMARDs as per NICE TA543 (APCO November 2018).
  • moderately to severely active ulcerative colitis as per NICE TA547 (APCO January 2019).
Link  NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Link  NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Link  NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
 

Red View adult BNF  View SPC online  View childrens BNF  HCD